These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34391930)

  • 1. Precautions after vaccinating immunosuppressed patients with mRNA-based vaccines against SARS-CoV-2: does one size fit all?
    Tau N; Manuel O; Rozen-Zvi B; Shargian L; Yahav D
    Clin Microbiol Infect; 2021 Dec; 27(12):1727-1728. PubMed ID: 34391930
    [No Abstract]   [Full Text] [Related]  

  • 2. The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.
    Malek AE; Cornejo PP; Daoud N; Alam M
    Immunotherapy; 2022 Feb; 14(2):91-94. PubMed ID: 34747190
    [No Abstract]   [Full Text] [Related]  

  • 3. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
    O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
    Front Immunol; 2021; 12():800723. PubMed ID: 34992610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA COVID-19 vaccines in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Montserrat E
    Eur J Haematol; 2022 Mar; 108(3):264-267. PubMed ID: 34856031
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Jacquérioz F
    Rev Med Suisse; 2022 Feb; 18(769):298. PubMed ID: 35188356
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Thompson MG; Natarajan K; Irving SA; Rowley EA; Griggs EP; Gaglani M; Klein NP; Grannis SJ; DeSilva MB; Stenehjem E; Reese SE; Dickerson M; Naleway AL; Han J; Konatham D; McEvoy C; Rao S; Dixon BE; Dascomb K; Lewis N; Levy ME; Patel P; Liao IC; Kharbanda AB; Barron MA; Fadel WF; Grisel N; Goddard K; Yang DH; Wondimu MH; Murthy K; Valvi NR; Arndorfer J; Fireman B; Dunne MM; Embi P; Azziz-Baumgartner E; Zerbo O; Bozio CH; Reynolds S; Ferdinands J; Williams J; Link-Gelles R; Schrag SJ; Verani JR; Ball S; Ong TC
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):139-145. PubMed ID: 35085224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: Third dose of mRNA-based COVID-19 vaccines for immunocompromised persons.
    Med Lett Drugs Ther; 2021 Sep; 63(1633):145-146. PubMed ID: 34550960
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines.
    Zinatizadeh MR; Zarandi PK; Zinatizadeh M; Yousefi MH; Amani J; Rezaei N
    Biomed Pharmacother; 2022 Feb; 146():112527. PubMed ID: 34906769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and novel mRNA vaccines in pregnancy: an updated literature review.
    Joubert E; Kekeh AC; Amin CN
    BJOG; 2022 Jan; 129(1):21-28. PubMed ID: 34651406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022.
    Ferdinands JM; Rao S; Dixon BE; Mitchell PK; DeSilva MB; Irving SA; Lewis N; Natarajan K; Stenehjem E; Grannis SJ; Han J; McEvoy C; Ong TC; Naleway AL; Reese SE; Embi PJ; Dascomb K; Klein NP; Griggs EP; Konatham D; Kharbanda AB; Yang DH; Fadel WF; Grisel N; Goddard K; Patel P; Liao IC; Birch R; Valvi NR; Reynolds S; Arndorfer J; Zerbo O; Dickerson M; Murthy K; Williams J; Bozio CH; Blanton L; Verani JR; Schrag SJ; Dalton AF; Wondimu MH; Link-Gelles R; Azziz-Baumgartner E; Barron MA; Gaglani M; Thompson MG; Fireman B
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):255-263. PubMed ID: 35176007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with messenger RNA vaccines against COVID-19 in adolescents with a history of multisystem inflammatory syndrome: a case series.
    Curtti T; Agrimbau Vázquez J; Yori S; Kantarovsky A; Torolla J; Di Santo M; Hammermüller E; Urrutia L; Parra A
    Arch Argent Pediatr; 2023 Jun; 121(3):e202202757. PubMed ID: 36194695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Audio Interview: Protecting the Immunosuppressed against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 May; 384(21):e88. PubMed ID: 34042395
    [No Abstract]   [Full Text] [Related]  

  • 13. What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?
    Silvestris N
    EBioMedicine; 2021 Dec; 74():103733. PubMed ID: 34864362
    [No Abstract]   [Full Text] [Related]  

  • 14. Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases.
    Cozzani E; Gasparini G; Sticchi L; Russo R; Icardi G; Parodi A
    Eur J Dermatol; 2021 Jun; 31(3):415-417. PubMed ID: 34309530
    [No Abstract]   [Full Text] [Related]  

  • 15. Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Alexander JL; Selinger CP; Powell N;
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):987-988. PubMed ID: 34653395
    [No Abstract]   [Full Text] [Related]  

  • 16. Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.
    Baron F; Canti L; Ariën KK; Kemlin D; Desombere I; Gerbaux M; Pannus P; Beguin Y; Marchant A; Humblet-Baron S
    Front Immunol; 2022; 13():827242. PubMed ID: 35309332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
    Embi PJ; Levy ME; Naleway AL; Patel P; Gaglani M; Natarajan K; Dascomb K; Ong TC; Klein NP; Liao IC; Grannis SJ; Han J; Stenehjem E; Dunne MM; Lewis N; Irving SA; Rao S; McEvoy C; Bozio CH; Murthy K; Dixon BE; Grisel N; Yang DH; Goddard K; Kharbanda AB; Reynolds S; Raiyani C; Fadel WF; Arndorfer J; Rowley EA; Fireman B; Ferdinands J; Valvi NR; Ball SW; Zerbo O; Griggs EP; Mitchell PK; Porter RM; Kiduko SA; Blanton L; Zhuang Y; Steffens A; Reese SE; Olson N; Williams J; Dickerson M; McMorrow M; Schrag SJ; Verani JR; Fry AM; Azziz-Baumgartner E; Barron MA; Thompson MG; DeSilva MB
    MMWR Morb Mortal Wkly Rep; 2021 Nov; 70(44):1553-1559. PubMed ID: 34735426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
    Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
    Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [COVID-19 vaccines and cancer patients: State of the art and guidelines summary].
    Kharmoum S; El M'Rabet FZ
    Bull Cancer; 2021 May; 108(5):553-555. PubMed ID: 33902920
    [No Abstract]   [Full Text] [Related]  

  • 20. Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.
    Al Jalali V; Scherzer S; Zeitlinger M
    Clin Microbiol Infect; 2021 Oct; 27(10):1529-1530. PubMed ID: 34192576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.